A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AHB 137 (Primary)
Indications Hepatitis B
Focus Adverse reactions; Pharmacokinetics
Sponsors AusperBio

Most Recent Events

11 Feb 2025 According to an AusperBio media release, interim Phase IIa study data presented in a late-breaking oral presentation at the 2024 AASLD Liver Meeting.
05 Nov 2024 Status changed from recruiting to active, no longer recruiting.
07 Aug 2024 Phase of study changed from phase 1 to phase1/2, treatment arms changed from 2 to 3

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight